Bacil Pharma Ltd
NSE: BSE: 524516
₹48.10
(-5.00%)
Sun, 15 Mar 2026, 02:06 pm
Market Cap726.69M
PE Ratio40.10
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KBacil Pharma Analysis
dividend
- Unable to evaluate Bacil Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Bacil Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Debt is covered by short term assets, assets are 4x debt.
- Bacil Pharma's level of debt (5.8%) compared to net worth is satisfactory (less than 40%).
- Low level of unsold assets.
- Bacil Pharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- Bacil Pharma's long term commitments exceed its cash and other short term assets.
- The level of debt compared to net worth has increased over the past 5 years (1.5% vs 5.8% today).
management
- The average tenure for the Bacil Pharma board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Manmohan's remuneration is lower than average for companies of similar size in India.
- Manmohan's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Bacil Pharma is not covered by any analysts.
- Bacil Pharma has significant price volatility in the past 3 months.
past
- Unable to compare Bacil Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Bacil Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Bacil Pharma has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Bacil Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Bacil Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Bacil Pharma's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Bacil Pharma is good value based on assets compared to the IN Pharmaceuticals industry average.
- Bacil Pharma is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Bacil Pharma is loss making, we can't compare the value of its earnings to the India market.
- BSE:524516 is down -4.6% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524516 is down -4.6% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800